Retirement Guys Formula LLC Has $200,000 Stock Holdings in Galectin Therapeutics Inc. (NASDAQ:GALT)

Retirement Guys Formula LLC lifted its holdings in Galectin Therapeutics Inc. (NASDAQ:GALT) by 143.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 155,343 shares of the company’s stock after buying an additional 91,526 shares during the period. Retirement Guys Formula LLC’s holdings in Galectin Therapeutics were worth $200,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of GALT. Sovran Advisors LLC acquired a new stake in shares of Galectin Therapeutics in the fourth quarter worth $240,000. Soltis Investment Advisors LLC acquired a new stake in shares of Galectin Therapeutics in the third quarter worth $387,000. Sanctuary Advisors LLC acquired a new stake in shares of Galectin Therapeutics in the second quarter worth $227,000. Kovitz Investment Group Partners LLC acquired a new stake in shares of Galectin Therapeutics in the third quarter worth $117,000. Finally, Geneos Wealth Management Inc. boosted its position in shares of Galectin Therapeutics by 10.2% in the fourth quarter. Geneos Wealth Management Inc. now owns 388,935 shares of the company’s stock worth $502,000 after buying an additional 36,000 shares during the period. Institutional investors and hedge funds own 11.68% of the company’s stock.

Galectin Therapeutics Stock Up 0.8 %

Shares of NASDAQ:GALT opened at $1.31 on Wednesday. Galectin Therapeutics Inc. has a fifty-two week low of $0.73 and a fifty-two week high of $4.27. The business has a 50-day moving average of $1.39 and a two-hundred day moving average of $2.17.

Wall Street Analyst Weigh In

Several analysts have recently commented on the company. StockNews.com cut Galectin Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, December 30th. HC Wainwright reissued a “neutral” rating on shares of Galectin Therapeutics in a research report on Friday, December 27th.

Insiders Place Their Bets

In other Galectin Therapeutics news, CFO Jack W. Callicutt sold 40,000 shares of the business’s stock in a transaction dated Monday, December 23rd. The stock was sold at an average price of $0.89, for a total value of $35,600.00. Following the completion of the sale, the chief financial officer now owns 7,614 shares of the company’s stock, valued at $6,776.46. The trade was a 84.01 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Joel Lewis sold 56,000 shares of the business’s stock in a transaction dated Monday, December 23rd. The stock was sold at an average price of $0.89, for a total value of $49,840.00. Following the completion of the sale, the chief executive officer now directly owns 897,012 shares of the company’s stock, valued at $798,340.68. This represents a 5.88 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 109,654 shares of company stock valued at $97,456 over the last quarter. Insiders own 50.10% of the company’s stock.

About Galectin Therapeutics

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.